Johnson & Johnson (NYSE:JNJ) Trading Up 1.2% – Here’s Why

Johnson & Johnson (NYSE:JNJ) shares rose 1.2% on Monday . The company traded as high as $231.45 and last traded at $231.1220. Approximately 8,393,272 shares traded hands during mid-day trading, a decline of 0% from the average session volume of 8,398,648 shares. The stock had previously closed at $228.39.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson said it will invest more than $1 billion to expand its Vision manufacturing, packaging, and distribution operations in Jacksonville, Florida, supporting higher domestic ACUVUE contact lens production and reinforcing its broader $55 billion U.S. manufacturing and R&D push. Johnson & Johnson (JNJ) Is Spending More Than $1 Billion On Jacksonville Vision Expansion
• Positive Sentiment: Several recent articles highlighted JNJ as an attractive long-term healthcare holding, with one note calling it a strong portfolio option and another citing a “moderate buy” consensus from brokerages, which can support investor confidence in the stock. Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating Johnson & Johnson (NYSE:JNJ) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Analysts and commentary also pointed to JNJ’s ongoing pharma momentum and dividend strength, but these were mainly valuation and outlook pieces rather than new company-specific catalysts. Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Weiss Ratings downgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. HSBC lifted their target price on Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a report on Wednesday, May 13th. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Finally, The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Trading Up 1.2%

The company has a 50-day moving average price of $230.61 and a two-hundred day moving average price of $228.25. The stock has a market cap of $556.36 billion, a P/E ratio of 26.72, a P/E/G ratio of 2.24 and a beta of 0.26. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period in the prior year, the company posted $2.77 EPS. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s payout ratio is 61.97%.

Insider Buying and Selling

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Blueline Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $25,000. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson in the fourth quarter valued at about $26,000. DecisionPoint Financial LLC boosted its holdings in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares in the last quarter. Family CFO Inc purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $31,000. Finally, Bay Harbor Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.